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ORIGINAL ARTICLE
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ABSTRACT
Background and purpose: In early-stage classical Hodgkin lymphoma (HL) the target volume
nowadays consists of the volume of the originally involved nodes. Delineation of this volume on a
post-chemotherapy CT-scan is challenging. We report on the interobserver variability in target volume
definition and its impact on resulting treatment plans.
Materials and methods: Two representative cases were selected (1: male, stage IB, localization: left
axilla; 2: female, stage IIB, localizations: mediastinum and bilateral neck). Eight experienced observers
individually defined the clinical target volume (CTV) using involved-node radiotherapy (INRT) as defined
by the EORTC-GELA guidelines for the H10 trial. A consensus contour was generated and the standard
deviation computed. We investigated the overlap between observer and consensus contour [Sørensen-
Dice coefficient (DSC)] and the magnitude of gross deviations between the surfaces of the observer
and consensus contour (Hausdorff distance). 3D-conformal (3D-CRT) and intensity-modulated radiother-
apy (IMRT) plans were calculated for each contour in order to investigate the impact of interobserver
variability on each treatment modality. Similar target coverage was enforced for all plans.
Results: The median CTV was 120 cm3 (IQR: 95–173 cm3) for Case 1, and 255 cm3 (IQR: 183–293 cm3)
for Case 2. DSC values were generally high (>0.7), and Hausdorff distances were about 30mm. The
SDs between all observer contours, providing an estimate of the systematic error associated with delin-
eation uncertainty, ranged from 1.9 to 3.8mm (median: 3.2mm). Variations in mean dose resulting
from different observer contours were small and were not higher in IMRT plans than in 3D-CRT plans.
Conclusions: We observed considerable differences in target volume delineation, but the systematic
delineation uncertainty of around 3mm is comparable to that reported in other tumour sites.
This report is a first step towards calculating an evidence-based planning target volume margin for
INRT in HL.
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Introduction
Radiotherapy (RT) for Hodgkin lymphoma (HL) has changed
dramatically during the past decades. When RT was the pri-
mary treatment modality, very extensive treatment fields
were used to encompass not only the macroscopic lymph-
oma but also possible microscopic disease. Total or subtotal
nodal irradiation encompassing all the major lymph node
areas was used routinely in early stage disease. With the
advent of effective chemotherapy, it became clear that these
large prophylactic treatment fields were no longer needed
[1] and involved-field RT (IFRT), including only regions with
involved lymph nodes, became the standard [2]. Soon after,
studies of patients treated with chemotherapy alone showed
that recurrences occurred most often at the site of initial
macroscopic lymphoma involvement [3]. Using FDG-PET to
identify this initial involvement, and modern 3-dimensional
(3D) conformal treatment planning to target it, it became
possible to reduce the treatment volume even further. The
EORTC (European Organisation for the Research and
Treatment of Cancer) Lymphoma Group pioneered this lim-
ited RT for early stage HL, called involved-node radiotherapy
(INRT) [4,5]. With INRT, the clinical target volume (CTV)
includes only the volume of initially involved lymph nodes,
as identified on PET/CT before chemotherapy is administered,
without compromising the effectiveness of the treatment
[6–8].
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Conformal radiotherapy makes precise target definition
essential in all treatment sites. In HL, and in other types of lym-
phomas as well, these issues are particularly challenging
because of the highly variable anatomical disease localizations
among patients and because of the inherent difficulty of defin-
ing the pre-chemotherapy lymphoma volume on a post-
chemotherapy planning CT-scan. In addition, the CTV also
includes volumes looking suspicious on CT but not PET posi-
tive. Genovesi et al. [9] reported variations in CTV volumes of
up to 1000 cm3 among observers contouring IFRT in supra-dia-
phragmatic HL without information from FDG-PET scans and in
the absence of contouring guidelines. Piva et al. [10] reported
similar results in a case of primary mediastinal B-cell lymph-
oma, despite using deformable image registration to fuse pre-
and post-chemotherapy images. Though these reports have
raised awareness about the challenges of delineation in HL,
they do not reflect a ‘best case scenario’ context in which INRT
can be applied, namely having the pre-chemotherapy PET/CT
scan performed in treatment position in order to minimize the
geometric uncertainties related to image fusion with the post-
chemotherapy planning CT-scan.
In this study, we report on the interobserver variability in
target volume delineation in close to optimal pre- and post-
chemotherapy imaging conditions as defined by the pub-
lished INRT guidelines [4] and using the expertise from the
Radiotherapy Committee of The EORTC Lymphoma Group.
We also investigate whether the dosimetric impact of this
interobserver variation is greater for more conformal techni-




In order to test the EORTC-GELA (Groupe d’Etude des
Lymphomes de l’Adulte, presently known as the Lymphoma
Study Association or LYSA) contouring guidelines for INRT as
applied in the H10 trial [6], two cases, typical of early stage HL,
were selected. Case no. 1 (male) had clinical stage (CS) IB dis-
ease in the left axilla and was treated with four cycles of ABVD
(Adriamycin, Bleomycin, Vinblastine and Dacarbazine) followed
by INRT. Case no. 2 (female) had CS IIB disease in the mediasti-
num and bilateral neck and was treated with six cycles of ABVD
followed by INRT.
The patients were scanned as recommended in the INRT
guidelines [4]. Both patients were staged using whole body
18F-Fluorodeoxyglucose (FDG) PET/CT-scans performed before
chemotherapy (from now referred to as ‘the pre-chemo PET/CT
scan’). The pre-chemo PET/CT scans were acquired on a
Siemens Biograph 40 (Siemens Healthineers, Erlangen,
Germany) exactly 1 hour after injection of 400 MBq of FDG.
Care was taken to acquire these images on a flat table top and
in the same position as would later be used for the radiother-
apy planning CT scan performed after chemotherapy (referred
to as ‘the post-chemo CT scan’). The initial PET-positive volume
was defined by visual evaluation of the FDG uptake, and was
contoured on the pre-chemo PET/CT-scan by a nuclear medi-
cine specialist as was standard practice in the host institution.
Contouring process
Contouring on the post-chemo CT scan and radiotherapy
planning were carried out using the EclipseVR software from
Varian Medical Systems (Palo Alto, CA). Scans and informa-
tion were all anonymized and all contouring was performed
at the institution where the patients were treated.
Eight individual radiation oncologists, each highly experi-
enced in contouring for HL, participated in this study met at
the host institution in order to contour on separate computers
over the course of a single day and were blinded both to each
other’s contours and to the contours used for the patients’
treatment. One of them (Observer 2) contoured in collabor-
ation with an experienced radiologist, as was standard practice
in their institution. All observers contoured the initially
involved volume on the pre-chemo PET/CT-scan with the help
of the already contoured PET-positive volume. The decision as
to which lymph nodes were involved initially was made on the
basis of all available information including clinical and radio-
logical information, the post-chemo CT-scan and published
guidelines [11]. The pre-chemo images were then fused with
the post-chemo CT-scan. Each observer then modified the con-
tours of the initially involved volume on the post-chemo CT-
scan to allow for shrinkage of tissues from pre- to post-chemo
scans, and to allow for uncertainties as deemed necessary. The
resulting volume, defined as the tissue volume that contained
the initially involved lymph nodes, was named the CTV and
defined the tissue volume that each observer considered as
needing irradiation.
Assessment of the interobserver variability
The CTV and planning target volume (PTV) from all observers
were reported for each case. In order to facilitate the presenta-
tion of the data, a consensus contour was generated using an
expectation-maximization algorithm for simultaneous truth
and performance level estimation (‘STAPLE’ [12]) integrated in
the publicly available research environment CERR [13] with a
confidence level of 80% (chosen after visual evaluation). This
algorithm has previously been used for the assessment of inter-
observer variation in radiotherapy [14,15]; in principle, the
algorithm considers the whole collection of submitted CTV
contours and generates a probabilistic estimate of the ‘true’
CTV contour. The overlap between observer and consensus
contour was investigated using the Sørensen-Dice similarity
coefficient (DSC) [16,17], defined as:
DSC ¼ 2 A\ Bð Þ
Aþ B
The magnitude of gross deviations between the surfaces
of the observer and consensus contour was investigated
using the Hausdorff distance [18] defined as:
‘Hausdorff distance’ (Hd) or the maximum separation
between two contours: Hd X; Yð Þ ¼ maxx2Xðminy2Y dðx; yÞÞ.
In the context of radiotherapy, the Hausdorff distance can
be thought of as reflecting the difference in beam aperture
designed for different target volumes.
An ideal agreement between the surfaces of contours would































All metrics were computed using the freeware 3D Slicer version
4.4 (www.slicer.org [19]) and the extension SlicerRT [20].
The interobserver variation can be handled as a geometric
uncertainty and included in the PTV margin using a margin
recipe as a systematic geometric error [21]. In order to derive
the systematic uncertainty resulting from the interobserver
variation in this study, an in-house matlab script was designed
to calculate the SD between the surfaces of the observer con-
tours in 6 directions (anterior, posterior, superior, inferior, right
and left). Using the margin recipe described by van Herk [22],
the SD can then be multiplied by 2.5 in order to provide a mar-
gin estimate accounting only for the interobserver variation
(i.e. assuming other geometric uncertainties such as organ
motion or patient set-up are equal to 0).
Treatment planning
In more conformal techniques such as IMRT, interobserver
variability may have a larger impact on the resulting dose
distribution compared to simple forms of 3D-CRT (e.g. two
opposing fields). In order to test this hypothesis, treatment
plans were made based on each contour from the eight
observers, using the current standard CTV-to-PTV margins
recommended in the International Lymphoma Radiation
Oncology Group (ILROG) guidelines [23]: a 1 cm isotropic
margin was added, except for the case with mediastinal
involvement (Case 2) where a 1.5 cm margin was added in
the superior-inferior direction, as is recommended to account
for respiration motion. All PTVs were then retracted 5mm
under the skin. For each set of contours, a 3D-CRT plan and
an IMRT plan were generated. 3D-CRT plans often consisted
of two opposing fields, with the addition of smaller fields to
improve the dose homogeneity (‘field-in-field’). IMRT plans
used 4–5 different beam angles chosen to minimize entry
through the organs at risk. The dose to the PTV was specified
as 30.6 Gy in 17 fractions, 5 fractions per week. A total of
2 2  8 treatment plans were calculated using the Analytic
Anisotropic Algorithm (version 13, Varian Medical Systems).
Similar target coverage was enforced for all plans, so that
95% of the PTV received at least 95% of the prescribed dose.
The maximum dose accepted in the PTV (or any part of the
body) was 107% of the prescribed dose. For IMRT plans, con-
straints were applied on the heart, lungs and female breasts
(for Case 2) to achieve ‘as low as possible’ a dose to those
organs. The resulting mean doses to the heart and lungs, as
well as the percentage of body volume receiving over 95%
of the prescribed dose (V95%), were estimated for both
cases. For Case 2, the mean dose to the female breasts, thy-
roid and carotid artery were also reported.
Results
Assessment of the interobserver variability
The volumes of the CTVs defined by the eight observers and
their associated PTVs are shown in Tables 1 and 2. The
median CTV was 120 cm3 (IQR: 95–173 cm3) for Case 1, and
255 cm3 (IQR: 183–293 cm3). Compared to the consensus con-
tours, this represented variations of 155% to 39% for Case
1 and of 157% to 72% for Case 2. These variations were
carried on to the PTV volumes, with differences up to
268 cm3 for Case 1 and 366 cm3 for Case 2.
Representative slices with all observer contours as well the
consensus contour are shown in Figures 1 and 2. DSC values
were generally high (>0.7), and the Hausdorff distances were
around 30mm, with the notable exception of Observer 8 (Case
1), where the CTV was drawn as small ‘islands’ (visible in Figure
1). This configuration, however, did not lead to a smaller PTV
size than for other observers: the PTV for Observer 8 is very
close to the median PTV (373 vs. 389 cm3) even though the
CTV was five times smaller than the median CTV.
The systematic uncertainty resulting from interobserver
variation, expressed as the SD between all observer contours
in each direction, is reported in Supplementary Table S1 and
ranged between 1.9 and 3.8mm, with a median of 3.2mm.
Impact on treatment planning
All plans satisfied the PTV coverage criterion of 95% of the
prescription dose to 95% of the PTV. The maximum dose
allowed was kept under 107%, though this condition was dif-
ficult to fulfil for 3D-CRT plans and small hot spots of up to
110% were occasionally accepted. The DVHs for the heart
and lungs are presented in Figures 3 and 4.
The resulting mean doses to the heart were low; around
0.3 Gy for Case 1 and 0.9Gy for Case 2 (see Supplementary
Tables S2 and S3). For Case 1, variations in mean dose were
under 0.2 Gy for the heart and 1.2 Gy for the lungs across the
group of observers, considering both treatment modalities.
For Case 2, mean heart dose variations were under 0.4 Gy
with the noticeable exception of Observer 7. There, the CTV
encompassed more tissue in the inferior direction (Figure 2)
and consequently led to a noticeably higher dose to the
heart (for both modalities) and lungs (for IMRT) as observed
by the DVHs in Figure 4. The resulting mean heart dose was
Table 1. Volume and overlap data for Case 1. Sørensen-Dice coefficients (DSC)
and Hausdorff distances are calculated for the CTV volumes with respect to
the consensus contour.
Observer CTV (cm3) PTV (cm3) DSC Hausdorff (mm)
1 215 615 0.73 28.1
2 99 347 0.69 29.9
3 162 449 0.80 17.4
4 128 405 0.80 18.5
5 206 544 0.88 11.0
6 84 364 0.64 14.9
7 112 354 0.74 35.1
8 21 373 0.24 47.5
Median 120 389 0.74 23.3
Consensus 176 544 ref ref
Table 2. Volume and overlap data for Case 2. Sørensen-Dice coefficients (DSC)
and Hausdorff distances are calculated for the CTV volumes with respect to
the consensus contour.
Observer CTV (cm3) PTV(cm3) DSC Hausdorff (mm)
1 370 986 0.74 30.8
2 192 653 0.74 19.2
3 336 827 0.87 11.0
4 240 689 0.81 18.1
5 279 780 0.89 13.2
6 157 620 0.67 20.9
7 270 728 0.88 12.6
8 141 874 0.64 17.5
Median 255 754 0.78 17.8
Consensus 298 858 ref ref






























then increased to 4.4Gy (3D CRT) and 3.7Gy (IMRT) in
Supplementary Table S3. This increase was also present
though less pronounced for the lungs and the breasts
(Supplementary Table S4).
Discussion
Inter- and intraobserver differences in the contouring of the
gross tumour volume (GTV) and CTV have been reported in
many tumour types and introduce a systematic geometrical
uncertainty that must be taken into account in the subsequent
planning process [22]. Quantifying this uncertainty is a difficult
process and is usually performed using one or two representa-
tive patient examples [9,10,14]. Interobserver studies cannot
claim to represent a whole clinical area or reflect the range of
complexity of all patient cases. However, such studies offer a
baseline for what is achievable, and a benchmark for other
institutions developing their own treatment procedures and
delineation guidelines. In our study, we chose to present two
typical (as opposed to challenging) HL cases and to include
only experts in the group of observers. Combined to the close-
to-optimal imaging conditions and INRT approach, we believe
it represents a ‘best case scenario’ situation which is substan-
tially different from the two previously published reports of
delineation uncertainty in HL [9,10].
Contouring for radiotherapy in the setting of modern
combined modality treatment of early stage HL poses special
challenges. In this situation, a volume which contained
lymphoma before chemotherapy is contoured on a post-
chemotherapy scan where most or all of the initial lymph-
oma has disappeared, and where shrinkage and deformation
of the surrounding normal tissues have happened to varying
degrees. This resembles in many ways the situation of post-
operative radiotherapy in other tumour types, e.g. in head
and neck cancer. In view of these challenges, it is reassuring
to observe that the interobserver variability was on the same
order of magnitude as has been reported for other indica-
tions, such as locally advanced lung cancer (4–5mm [24]),
Figure 1. Delineations from the eight expert observers (in white) and generated consensus contour (in red) for Case 1. Note the presence of a contour drawn as
small ‘islands’, especially visible in the transverse view (top left).
Figure 2. Delineations from the eight expert observers (in white) and generated consensus contour (in red) for Case 2. Note that one observer included more tissue































breast-conserving radiotherapy (2–8mm, estimated from [25])
or prostate cancer (1.7–3.5mm [22]).
It should, however, be noted that this level of confidence
can only be achieved with dedicated radiation oncologists,
knowledgeable of the disease, as well as an optimal use of
imaging. It is strongly recommended to use PET as part of
the pre-chemotherapy evaluation when planning to use
highly conformal INRT after chemotherapy, as PET signifi-
cantly improves the detection of involved sites in patients
with HL [26,27]. It is also recommended that the pre-
chemotherapy PET/CT-scan be acquired with the patient
in the same position as will later be used for RT. Strict
adherence to this principle is necessary if fusion of the pre-
chemotherapy PET/CT images with the post-chemotherapy
planning CT-images is to be used successfully. If this is not
achievable, or if in spite of correct positioning the fusion of
the pre- and post-chemotherapy images remains sub-optimal
(e.g. if the patient loses weight), those additional uncertain-
ties will mandate the use of larger margins to secure cover-
age of the initially involved volume [23].
In this study, the interobserver variability led to marked
differences in CTV volume. These differences are mitigated
by the generation of the PTV margin, though large discrep-
ancies remain. For example, for Case 1, the PTV size for
Observer 1 is almost double that for Observer 2. The impact
of this variability on the dose to OARs appears modest, as
the disease location was favourably far from major OARs in
both cases. The mean doses to the heart, lung and breasts
were slightly higher with IMRT than with 3D-CRT but all
remained very low. There is one notable exception: for Case
2, Observer 7, the mean heart dose was about 3.5 Gy higher
than for all other observers, even though the corresponding
PTV size, DSC and Hausdorff distance were all well within the
reported range for other observers. This illustrates two
things: (1) that all the mentioned metrics fail to fully repre-
sent the variability in doses received by the OARs and (2)
that a few millimeters of difference in contouring can have a
considerable impact on the dose to neighbouring OARs. This
last difference will likely become even more substantial for
novel treatment modalities such as proton therapy. Though a
Figure 3. DVH of the dose received by the heart and for all observer contours in Case 1. Results are shown for 3D conformal plans (left) as well as intensity-modu-
lated radiotherapy plans (right).
Figure 4. DVH of the dose received by the heart and for all observer contours in Case 2. Results are shown for 3D conformal plans (left) as well as intensity-modu-
lated radiotherapy plans (right).






























certain degree of variability is inevitable even within an
expert group, efforts such as guidelines or ‘collaborative’ con-
touring (with at least two observers present at the time of
delineation) have been suggested to effectively decrease the
risk of outliers and should be encouraged.
Determining the SD between the observer contours is a first
step towards calculating an evidence-based PTV margin for
INRT in HL. The present results suggest that the systematic
delineation uncertainty is around 3mm, which alone would
result in a CTV to PTV margin of almost 8mm (according to the
van Herk’s formula [22]), very close to the 10mm recom-
mended by ILROG. In practice, other uncertainties, such as
image fusion and patient set-up, must be included in a thor-
ough margin recipe and can only increase the total PTV margin
required. The limitations of our study include the small number
of patient cases and relatively small number of observers. The
clinical cases selected for this study, though fairly typical of
early-stage HL, have smaller target volumes than the cases
selected by Genovesi et al. [9] and Piva et al. [10], which could
limit the comparison between these three studies in addition
to the differences in imaging conditions already stated. Finally,
all observers in this study were experienced with contouring
for INRT for HL, and this might not reflect the experience of
less experienced centres, or of centres using Involved Site
radiotherapy (ISRT). Even bearing these limitations in mind, we
believe that those results illustrate the potential of guidelines
and standardization, both for pre- and post-chemotherapy
imaging as well as for delineation of the CTV.
Conclusions
CTV volumes varied considerably between observers in both
clinical cases. However, the systematic delineation uncertainty
was around 3mm and is comparable to that reported in other
clinical situations. Results suggest that the dosimetric impact of
interobserver variation is not larger for IMRT than for 3D-CRT.
This study demonstrates that contouring target volumes for
conformal INRT in HL can be performed with the same interob-
server variability as can be achieved in other tumour types.
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